INCY

SEC source: 0000879169-25-000031 · wk-form4_1737579911.xml · nonDerivative · entry 1

Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,963

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 16,955 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0000879169-25-000041 · wk-form4_1737580194.xml · derivative · entry 1

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,772

Underlying: Common Stock · 14,772 shares

Expires 2035-01-16

F1 · derivative.exercise_date: Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years.

SEC source: 0000879169-25-000039 · wk-form4_1737580138.xml · derivative · entry 1

Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,516

Underlying: Common Stock · 25,516 shares

Expires 2035-01-16

F1 · derivative.exercise_date: Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years.

SEC source: 0000879169-25-000040 · wk-form4_1737580167.xml · derivative · entry 1

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,772

Underlying: Common Stock · 14,772 shares

Expires 2035-01-16

F1 · derivative.exercise_date: Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years.

SEC source: 0000879169-25-000035 · wk-form4_1737580032.xml · derivative · entry 1

CAGNONI PABLO J · CIK 0001205703 · President, R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,289

Underlying: Common Stock · 40,289 shares

Expires 2035-01-16

F1 · derivative.exercise_date: Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years.

SEC source: 0000879169-25-000038 · wk-form4_1737580111.xml · derivative · entry 1

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,144

Underlying: Common Stock · 20,144 shares

Expires 2035-01-16

F1 · derivative.exercise_date: Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years.

SEC source: 0000879169-25-000037 · wk-form4_1737580084.xml · derivative · entry 1

Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,510

Underlying: Common Stock · 55,510 shares

Expires 2035-01-16

F1 · derivative.exercise_date: Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years.

SEC source: 0000879169-25-000036 · wk-form4_1737580058.xml · derivative · entry 1

Tray Thomas · CIK 0001912317 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,432

Underlying: Common Stock · 3,432 shares

Expires 2035-01-16

F1 · derivative.exercise_date: Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years.

SEC source: 0000879169-25-000034 · wk-form4_1737580004.xml · derivative · entry 1

Denton Sheila A. · CIK 0001995298 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,086

Underlying: Common Stock · 12,086 shares

Expires 2035-01-16

F1 · derivative.exercise_date: Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years.

SEC source: 0000879169-25-000032 · wk-form4_1737579939.xml · derivative · entry 2

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 28,202

Underlying: Common Stock · 28,202 shares

Expires 2035-01-16

F2 · derivative.exercise_date: Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years.

SEC source: 0000879169-25-000033 · wk-form4_1737579977.xml · derivative · entry 1

Trotta Matteo · CIK 0002015975 · EVP, GM, Dermatology US

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,371

Underlying: Common Stock · 5,371 shares

Expires 2035-01-16

F1 · derivative.exercise_date: Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years.

SEC source: 0000879169-25-000019 · wk-form4_1737146019.xml · nonDerivative · entry 1

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,374

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 33,554 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

SEC source: 0000879169-25-000018 · wk-form4_1737145989.xml · nonDerivative · entry 1

Morrissey Michael James · CIK 0001780915 · EVP, Head of Tech. Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,392

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 23,074 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0000879169-25-000016 · wk-form4_1737145906.xml · nonDerivative · entry 1

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,319

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 64,408 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested.

SEC source: 0000879169-25-000017 · wk-form4_1737145955.xml · nonDerivative · entry 1

Stamoulis Christiana · CIK 0001502917 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,525

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 46,753 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

SEC source: 0000879169-25-000009 · wk-form4_1736370662.xml · nonDerivative · entry 1

Issa Mohamed Khairie · CIK 0002050035 · EVP, Head of US Oncology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,671

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Includes the January 6, 2025 aggregate grant of 48,671 shares of common stock.

SEC source: 0000950170-25-001355 · ownership.xml · nonDerivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 28,184,084

F1 · shares: Includes 446 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $32,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F1 · ownership.nature: Includes 446 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $32,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Includes beneficial ownership of 12,543 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 9,374 shares of Common Stock received previously from vested restricted stock units payable solely in Common Stock (each an "RSU"), 2,830 shares of Common Stock underlying unvested RSUs and 230,000 shares of Common Stock received previously from the exercise of 230,000 non-qualified stock options exercisable solely into Common Stock ("Stock Options") that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds are deemed to own a portion.

F6 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F7 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F8 · ownership.nature: The acquisitions of RSUs reported on this form represent a single grant of 446 RSUs on Table I. The 446 RSUs are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F9 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-25-001355 · ownership.xml · nonDerivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,813,405

F1 · shares: Includes 446 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $32,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F1 · ownership.nature: Includes 446 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $32,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F2 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Includes beneficial ownership of 12,543 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 9,374 shares of Common Stock received previously from vested restricted stock units payable solely in Common Stock (each an "RSU"), 2,830 shares of Common Stock underlying unvested RSUs and 230,000 shares of Common Stock received previously from the exercise of 230,000 non-qualified stock options exercisable solely into Common Stock ("Stock Options") that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds are deemed to own a portion.

F6 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F7 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F8 · ownership.nature: The acquisitions of RSUs reported on this form represent a single grant of 446 RSUs on Table I. The 446 RSUs are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

SEC source: 0000879169-25-000004 · wk-form4_1735927599.xml · nonDerivative · entry 1

Clancy Paul J · CIK 0001409601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,713

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

F2 · balance_after: This includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0000879169-25-000003 · wk-form4_1735927555.xml · nonDerivative · entry 1

HARRIGAN EDMUND · CIK 0001177917 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,071

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

F2 · balance_after: This includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0000879169-24-000182 · wk-form4_1734457052.xml · nonDerivative · entry 2

Tray Thomas · CIK 0001912317 · Principal Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,312

F1 · balance_after: This includes an aggregate of 15,406 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0000879169-24-000182 · wk-form4_1734457052.xml · nonDerivative · entry 1

Tray Thomas · CIK 0001912317 · Principal Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,962

SEC source: 0000879169-24-000180 · wk-form4_1733941196.xml · nonDerivative · entry 1

SWAIN PAULA J · CIK 0001236934 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,203

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 27,325 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

SEC source: 0000879169-24-000179 · wk-form4_1733941156.xml · nonDerivative · entry 1

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,532

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 44,595 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

SEC source: 0000879169-24-000176 · wk-form4_1733248327.xml · nonDerivative · entry 2

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,658

F1 · balance_after: Includes an aggregate of 28,198 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

SEC source: 0000879169-24-000176 · wk-form4_1733248327.xml · nonDerivative · entry 1

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,341

SEC source: 0000879169-24-000174 · wk-form4_1731087831.xml · derivative · entry 6

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,256 shares

Expires 2028-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2019 and the remainder vesting monthly over three years.

SEC source: 0000879169-24-000174 · wk-form4_1731087831.xml · derivative · entry 5

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,424 shares

Expires 2029-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Beginning January 4, 2019, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2019 and the remainder vesting monthly over three years.

SEC source: 0000879169-24-000174 · wk-form4_1731087831.xml · nonDerivative · entry 4

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,042

F1 · balance_after: This includes an aggregate of 46,105 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

SEC source: 0000879169-24-000174 · wk-form4_1731087831.xml · nonDerivative · entry 3

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 60,298

SEC source: 0000879169-24-000174 · wk-form4_1731087831.xml · nonDerivative · entry 2

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 61,722

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000879169-24-000174 · wk-form4_1731087831.xml · nonDerivative · entry 1

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,466

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000879169-24-000165 · wk-form4_1728059987.xml · nonDerivative · entry 1

Denton Sheila A. · CIK 0001995298 · EVP & General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,343

F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F2 · balance_after: This includes an aggregate of 25,848 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance units that have not vested.

SEC source: 0000879169-24-000163 · wk-form4_1727976482.xml · nonDerivative · entry 1

Heeson Lee · CIK 0002039219 · EVP, Head of Incyte Intl

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,447

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2 · balance_after: Including the October 1, 2024 grant, this includes an aggregate of 26,447 shares of common stock issuable pursuant to previously reported RSUs that have not vested.

SEC source: 0000950170-24-111462 · ownership.xml · nonDerivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 28,183,638

F1 · shares: Includes 496 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $32,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F1 · ownership.nature: Includes 496 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $32,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Includes beneficial ownership of 12,047 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 9,374 shares of Common Stock received previously from vested restricted stock units payable solely in Common Stock (each an "RSU"), 2,830 shares of Common Stock underlying unvested RSUs and 230,000 shares of Common Stock received previously from the exercise of 230,000 non-qualified stock options exercisable solely into Common Stock ("Stock Options") that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds are deemed to own a portion.

F6 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F7 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F8 · ownership.nature: The acquisitions of RSUs reported on this form represent a single grant of 496 RSUs on Table I. The 496 RSUs are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F9 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-24-111462 · ownership.xml · nonDerivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,812,959

F1 · shares: Includes 496 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $32,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F1 · ownership.nature: Includes 496 shares of common stock ("Common Stock") of Incyte Corporation (the "Issuer") issued to Julian C. Baker pursuant to the Issuer's Amended and Restated 2010 Stock Incentive Plan (the "Stock Incentive Plan") in lieu of quarterly director retainer fees of $32,000. The shares of Common Stock are fully vested. Julian C. Baker serves on the Issuer's board of directors (the "Board") as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F2 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds or for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Includes beneficial ownership of 12,047 shares of Common Stock previously issued to Julian C. Baker pursuant to the Stock Incentive Plan in lieu of director retainer fees, 9,374 shares of Common Stock received previously from vested restricted stock units payable solely in Common Stock (each an "RSU"), 2,830 shares of Common Stock underlying unvested RSUs and 230,000 shares of Common Stock received previously from the exercise of 230,000 non-qualified stock options exercisable solely into Common Stock ("Stock Options") that were issued to Julian C. Baker in his capacity as a director of the Issuer, of which the Funds are deemed to own a portion.

F6 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options, Common Stock issued upon exercise of Stock Options, RSUs and Common Stock received upon vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F7 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Common Stock received in lieu of director retainer fees, Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F8 · ownership.nature: The acquisitions of RSUs reported on this form represent a single grant of 496 RSUs on Table I. The 496 RSUs are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

SEC source: 0000879169-24-000159 · wk-form4_1727888479.xml · nonDerivative · entry 1

Clancy Paul J · CIK 0001409601 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,382

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

F2 · balance_after: This includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0000879169-24-000158 · wk-form4_1727888444.xml · nonDerivative · entry 1

HARRIGAN EDMUND · CIK 0001177917 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,732

F1 · security: Restricted shares issued to the Reporting Person under the Issuer's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees pursuant to an election by the Reporting Person intended to comply with Rule 10b5-1. Restricted shares are fully vested.

F2 · balance_after: This includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0000879169-24-000155 · wk-form4_1726507506.xml · nonDerivative · entry 2

Tray Thomas · CIK 0001912317 · Principal Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,443

F1 · balance_after: This includes an aggregate of 15,406 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0000879169-24-000155 · wk-form4_1726507506.xml · nonDerivative · entry 1

Tray Thomas · CIK 0001912317 · Principal Accounting Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,825

SEC source: 0000879169-24-000154 · wk-form4_1726507450.xml · nonDerivative · entry 2

Dickinson Jonathan Elliott · CIK 0001780561 · EVP, General Manager, Europe

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,390

F1 · balance_after: This includes an aggregate of 21,270 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

SEC source: 0000879169-24-000154 · wk-form4_1726507450.xml · nonDerivative · entry 1

Dickinson Jonathan Elliott · CIK 0001780561 · EVP, General Manager, Europe

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,723

SEC source: 0000879169-24-000151 · wk-form4_1723664231.xml · nonDerivative · entry 1

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 90,011

F1 · balance_after: This includes an aggregate of 87,452 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested.

SEC source: 0000879169-24-000143 · wk-form4_1722282621.xml · nonDerivative · entry 1

Iyengar Vijay K · CIK 0001670000 · EVP, GMAPPS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,701

F1 · balance_after: This includes an aggregate of 28,198 shares of common stock issuable pursuant to previously report RSUs and earned performance shares that have not vested.

SEC source: 0000879169-24-000130 · wk-form4_1721233433.xml · nonDerivative · entry 3

Flannelly Barry P · CIK 0001615842 · EVP & General Manager US

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,042

F3 · balance_after: Including the July 15, 2024 grant, this includes an aggregate of 46,105 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

SEC source: 0000879169-24-000139 · wk-form4_1721233859.xml · derivative · entry 3

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,088

Underlying: Common Stock · 31,088 shares

Expires 2034-07-14

F4 · derivative.exercise_date: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0000879169-24-000139 · wk-form4_1721233859.xml · nonDerivative · entry 2

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,619

F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.

F3 · balance_after: Including the July 15, 2024 grant, this includes an aggregate of 87,452 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested.

SEC source: 0000879169-24-000139 · wk-form4_1721233859.xml · nonDerivative · entry 1

Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,174

F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to the employee's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis.

SEC source: 0000879169-24-000138 · wk-form4_1721233824.xml · derivative · entry 3

Tray Thomas · CIK 0001912317 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,783

Underlying: Common Stock · 3,783 shares

Expires 2034-07-14

F4 · derivative.exercise_date: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.

SEC source: 0000879169-24-000138 · wk-form4_1721233824.xml · nonDerivative · entry 2

Tray Thomas · CIK 0001912317 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,397

F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock.

F3 · balance_after: Including the July 15, 2024 grant, this includes an aggregate of 15,406 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.